BTAI

BioXcel Therapeutics, Inc. [BTAI] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

BTAI Stock Summary

Top 10 Correlated Stocks

BTAI


In the News

09:05 26 Feb 2024 BTAI

Why Is BioXcel Therapeutics (BTAI) Stock Down 26% Today?

BioXcel Therapeutics (NASDAQ: BTAI ) stock is taking a beating on Friday after the commercial-stage biopharmaceutical company announced a proposed underwritten public offering for its shares. This public offering includes $60 million shares of BTAI stock.

06:40 26 Feb 2024 BTAI

7 Penny Stocks With Low Floats and High Short Interest

There are many ways to approach penny stocks, but one that has gained popularity in recent years focuses on stocks in this category that are prime candidates for a “short squeeze.” A typical short squeeze candidate has a high level of short interest, or percentage of outstanding float sold short.

10:41 26 Feb 2024 BTAI

BioXcel Therapeutics stock plummets as 3Q earnings fall short of expectations

BioXcel Therapeutics Inc (NASDAQ:BTAI) shares fell almost 35% after it reported a revenue miss and greater than forecast loss for the third quarter. The New Haven, Connecticut-based biopharmaceutical company reported sales of $341,000, up from $137,000 in the year-ago quarter but below estimates of $840,000.

02:11 26 Feb 2024 BTAI

5 Most Active Penny Stocks Today & Why They're Moving Now

Penny stocks are the wild west of the stock market. Fast-paced, unpredictable, and laden with potential treasures.

02:18 26 Feb 2024 BTAI

Penny Stocks To Buy Today? 4 To Watch Now

Ready to dive into the volatile world of penny stocks? You've got your work cut out for yourself if this is your first foray into the stock market.

12:09 26 Feb 2024 BTAI

4 Penny Stocks To Watch Today With Big News, Time To Buy?

Trading penny stocks can be a risky endeavor, but having access to quality news and information can help mitigate some of that risk. As an investor or trader, it's critical to understand how news events can impact penny stocks and how to use news to your advantage when developing your trading strategy.

03:06 26 Feb 2024 BTAI

3 Penny Stocks To Buy For Under $5, Are They Worth It?

Penny stocks are defined as stocks trading for under $5. They typically include start-up or emerging-growth stage companies starting from the grassroots.

09:19 26 Feb 2024 BTAI

5 Hot Penny Stocks To Watch In The Stock Market Today

Whether you're looking for the best penny stocks to buy, the most active stocks today, or just trying to plan out your next long-term investment, understanding things like stock market news and events is important.

09:18 26 Feb 2024 BTAI

Why Is BioXcel Therapeutics (BTAI) Stock Up 42% Today?

BioXcel Therapeutics (NASDAQ: BTAI ) stock is rocketing higher on Wednesday after the biopharmaceutical company announced results from an audit of its Tranquility II clinical trial. According to a press release from the company, a third-party audit of its Phase 3 study returned positive results.

08:44 26 Feb 2024 BTAI

BioXcel Therapeutics shares pop after audit of Alzheimer's trial data

Shares of BioXcel Therapeutics Inc. BTAI, +0.86% jumped more than 40% premarket on Wednesday after the company said an independent audit of Alzheimer's trial data found no issues impacting the data's integrity and reliability.

BTAI Financial details

Company Rating
Neutral
Market Cap
93.27M
Income
-213.11M
Revenue
1.24M
Book val./share
-1.39
Cash/share
3.07
Dividend
-
Dividend %
-
Employees
183
Optionable
No
Shortable
Yes
Earnings
07 Mar 2024
P/E
-0.38
Forward P/E
-2.07
PEG
-0.05
P/S
65.29
P/B
-2
P/C
1
P/FCF
-0.49
Quick Ratio
2.3
Current Ratio
2.51
Debt / Equity
-2.45
LT Debt / Equity
-2.45
-
-
EPS (TTM)
-7.4
EPS next Y
-1.48
EPS next Q
1.58
EPS this Y
51.73%
EPS next Y
-80.04%
EPS next 5Y
-80.04%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-25.38%
EPS Q/Q
-6.01%
-
-
-
-
SMA20
10.47%
SMA50
-13.31%
SMA100
11.27%
Inst Own
31.42%
Inst Trans
0.52%
ROA
-212%
ROE
-897%
ROC
-3.36%
Gross Margin
55%
Oper. Margin
-16490%
Profit Margin
-17159%
Payout
-
Shs Outstand
30.38M
Shs Float
21.2M
-
-
-
-
Target Price
34
52W Range
1.91-32.87
52W High
-90.41%
52W Low
+207%
RSI
49.05
Rel Volume
0.86
Avg Volume
1.57M
Volume
1.35M
Perf Week
24.8%
Perf Month
12.45%
Perf Quarter
-18.78%
Perf Half Y
-23.82%
-
-
-
-
Beta
0.493
-
-
Volatility
0.21%, 0.51%
Prev Close
-3.15%
Price
3.07
Change
-5.83%

BTAI Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000.01
Net income per share
-1.32-1.99-3.78-4.04-6.13
Operating cash flow per share
-0.93-1.67-3.06-3.12-4.83
Free cash flow per share
-0.95-1.73-3.07-3.13-4.84
Cash per share
2.921.999.838.836.92
Book value per share
2.671.659.538.412.74
Tangible book value per share
2.671.659.538.412.74
Share holders equity per share
2.671.659.538.412.74
Interest debt per share
00.060.080.053.65
Market cap
56.25M237.98M1B536.16M601.76M
Enterprise value
13.68M206.59M790.27M304.59M502.19M
P/E ratio
-2.92-7.36-12.22-5.03-3.5
Price to sales ratio
00001.6K
POCF ratio
-4.16-8.72-15.1-6.53-4.45
PFCF ratio
-4.06-8.45-15.03-6.49-4.44
P/B Ratio
1.458.854.852.427.84
PTB ratio
1.458.854.852.427.84
EV to sales
00001.34K
Enterprise value over EBITDA
-0.66-6.06-9.6-2.85-3.19
EV to operating cash flow
-1.01-7.57-11.91-3.71-3.71
EV to free cash flow
-0.99-7.34-11.85-3.69-3.71
Earnings yield
-0.34-0.14-0.08-0.2-0.29
Free cash flow yield
-0.25-0.12-0.07-0.15-0.23
Debt to equity
00.040.010.011.23
Debt to assets
00.030.010.010.46
Net debt to EBITDA
2.060.922.572.170.63
Current ratio
9.264.0318.3313.986.17
Interest coverage
00-3.05K-2.67K-19.44
Income quality
0.70.830.810.770.82
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0000183.36
Research and developement to revenue
0000243.3
Intangibles to total assets
00000
Capex to operating cash flow
0.030.0300.010
Capex to revenue
0000-0.37
Capex to depreciation
-20-5.58-1.68-1.5-0.43
Stock based compensation to revenue
000046.23
Graham number
8.918.5928.4827.6519.45
ROIC
-0.53-1.14-0.39-0.48-0.96
Return on tangible assets
-0.44-0.89-0.37-0.45-0.83
Graham Net
2.611.419.228.162.35
Working capital
38.51M25.64M205.22M216.3M169.97M
Tangible asset value
38.89M26.9M206.7M221.67M76.78M
Net current asset value
38.51M24.61M203.83M215.2M73.79M
Invested capital
00.040.010.011.23
Average receivables
57.5K57.5K00124K
Average payables
1.02M3.28M4.47M4.33M7.45M
Average inventory
0000992.5K
Days sales outstanding
0000241.39
Days payables outstanding
0000186.66K
Days of inventory on hand
000036.23K
Receivables turnover
00001.51
Payables turnover
00000
Inventory turnover
00000.01
ROE
-0.5-1.2-0.4-0.48-2.24
Capex per share
-0.02-0.05-0.01-0.020

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00.010.010.020.01
Net income per share
-1.59-2.07-1.78-1.83-1.72
Operating cash flow per share
-1.11-1.38-1.83-1.31-1.28
Free cash flow per share
-1.11-1.38-1.83-1.31-1.28
Cash per share
8.296.95.784.373.07
Book value per share
4.532.741.850.2-1.39
Tangible book value per share
4.532.741.850.2-1.39
Share holders equity per share
4.532.741.850.2-1.39
Interest debt per share
3.213.463.483.463.51
Market cap
331.22M602.9M533.97M194.39M74.05M
Enterprise value
191.78M503.33M464.54M164.64M83.71M
P/E ratio
-1.86-2.59-2.62-0.91-0.37
Price to sales ratio
2.42K2.53K2.59K425.35217.15
POCF ratio
-10.62-15.6-10.2-5.09-1.97
PFCF ratio
-10.62-15.6-10.2-5.09-1.97
P/B Ratio
2.617.8510.0733.15-1.82
PTB ratio
2.617.8510.0733.15-1.82
EV to sales
1.4K2.11K2.26K360.25245.48
Enterprise value over EBITDA
-4.92-9.7-9.4-3.28-1.95
EV to operating cash flow
-6.15-13.03-8.87-4.31-2.23
EV to free cash flow
-6.15-13.03-8.87-4.31-2.23
Earnings yield
-0.13-0.1-0.1-0.28-0.68
Free cash flow yield
-0.09-0.06-0.1-0.2-0.51
Debt to equity
0.731.231.8116.68-2.45
Debt to assets
0.380.460.530.70.99
Net debt to EBITDA
3.581.921.40.59-0.22
Current ratio
10.346.176.163.982.51
Interest coverage
13.55-18.11-15.21-16.08-14.85
Income quality
0.750.70.990.710.74
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
124.4886.82114.5446.0962.62
Research and developement to revenue
161.04136.38134.9559.0257.53
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
000-0.040
Capex to depreciation
000-0.250
Stock based compensation to revenue
32.7219.1123.6713.411.77
Graham number
12.7411.298.622.887.34
ROIC
-0.19-0.33-0.33-0.54-0.86
Return on tangible assets
-0.18-0.28-0.28-0.38-0.5
Graham Net
4.262.351.38-0.19-1.69
Working capital
218.28M169.97M148.51M103.49M59.33M
Tangible asset value
126.99M76.78M53.01M5.86M-40.61M
Net current asset value
123.83M73.79M50.17M4M-42.32M
Invested capital
0.731.231.8116.68-2.45
Average receivables
6.95M2.88M265.5K357K583K
Average payables
5.95M8.05M8.99M9.47M10.94M
Average inventory
1.4M1.7M1.97M1.94M1.97M
Days sales outstanding
3.62K93.78123.6484.88193.99
Days payables outstanding
48.04K102.28K77.42K38.78K1.88K
Days of inventory on hand
11.52K19.85K19.52K6.66K354.73
Receivables turnover
0.020.960.731.060.46
Payables turnover
00000.05
Inventory turnover
0.01000.010.25
ROE
-0.35-0.76-0.96-9.131.24
Capex per share
00000

BTAI Frequently Asked Questions

What is BioXcel Therapeutics, Inc. stock symbol ?

BioXcel Therapeutics, Inc. is a US stock , located in New haven of Ct and trading under the symbol BTAI

Is BioXcel Therapeutics, Inc. buy or a sell ?

3 stock analysts have 3 predictions with a medium analyst target price of $34. The lowest prediction is $4 and the highest is $73

What is BTAI stock prediction ?

What is BioXcel Therapeutics, Inc. stock quote today ?

BioXcel Therapeutics, Inc. stock price is $3.07 today.

Is BioXcel Therapeutics, Inc. stock public?

Yes, BioXcel Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated Stocks
Similar Market Cap